GlaxoSmithKline (GSK) and Theravance have reported positive results from three Phase III trials comparing Anoro Ellipta with Seretide Diskus and Advair Diskus in patients with chronic obstructive pulmonary disease (COPD).

Out of the three, two trials compared the efficacy and safety of the combination anticholinergic / long-acting beta2-adrenergic agonist, Anoro Ellipta (umeclidinium/vilanterol, ‘UMEC/VI’) with inhaled corticosteroid / long-acting beta2-adrenergic agonist combination, Advair Diskus (fluticasone propionate/salmeterol ‘FSC 250/50’) in COPD patients .

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The third compared the efficacy and safety of Anoro Ellipta with Seretide Diskus ‘FSC 500/50’ in patients with COPD and no history of moderate to severe COPD exacerbations in the last year.

"These findings add to the existing body of evidence and our understanding of the efficacy and safety of UMEC/VI."

In each trial, UMEC/VI achieved a statistically significant improvement in lung function, measured as weighted mean forced expiratory volume in one second (wm FEV1) over 0-24 hours at the end of the 12 week study (day 84), compared with either dose of FSC.

GSK senior vice-president and head of global respiratory franchise Darrell Baker said: "These findings add to the existing body of evidence and our understanding of the efficacy and safety of UMEC/VI."

See Also:

About 2,100 patients with post-salbutamol FEV1 of = 30% and = 70% and no history of moderate to severe COPD exacerbations in the last 12 months have participated in all the three 12-week multicentre, randomised, double-blind, double-dummy, parallel group trials (116134, 114930 and 114951).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In these trials, eligible patients were given either UMEC/VI (62.5/25mcg) as a once-daily inhalation and placebo administered twice-daily, or FSC (500/50 mcg in study 116134 and 250/50mcg in studies 114930 and 114951) administered as a twice-daily inhalation and placebo administered once-daily.

The company said that UMEC/VI was administered in the dry powder inhaler (DPI), Ellipta and FSC in the multi-dose powdered inhaler, Diskus.